Yes, there are ongoing clinical trials investigating TNFR2-targeted therapies. These trials are exploring the efficacy and safety of TNFR2 inhibitors, either as monotherapy or in combination with other immunotherapies such as checkpoint inhibitors. Preliminary results are promising, showing enhanced anti-tumor activity and improved patient outcomes.
